Sangamo Therapeutics, Inc. (NASDAQ: SGMO) presents data in a podium presentation at the 14th International Conference on Alzheimer's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Sangamo Therapeutics (SGMO), Pfizer (PFE) Report Phase 1/2 Interim Data For Investigational Hemophilia A Gene TherapyApril 2, 2019 7:01 AM Sangamo Therapeutics (SGMO) to Host April 2 Conference Call To Provide Clinical UpdateApril 1, 2019 5:23 PM Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation TechnologyMarch 29, 2019 7:00 AM